/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Denali Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$19.37 0.065(6.5%) DNLI at 04 Dec 2025 04:29 PM Biotechnology
Lowest Today 18.1
Highest Today 19.14
Today’s Open 18.23
Prev. Close 17.84
52 Week High 26.18
52 Week Low 10.57
Day’s Range: Low 18.1 High 19.14
52-Week Range: Low 10.57 High 26.18
1 day return -
1 Week return -2.36
1 month return +27.44
3 month return +28.39
6 month return +31.69
1 year return -19.75
3 year return -38.68
5 year return -73.88
10 year return -

Institutional Holdings

BlackRock Inc 8.24

Baillie Gifford & Co Limited. 8.18

Vanguard Group Inc 8.08

FMR Inc 5.16

T. Rowe Price Associates, Inc. 4.50

Scottish Mortgage Ord 4.47

UBS Asset Mgmt Americas Inc 4.28

Wellington Management Company LLP 3.87

Temasek Holdings Ltd. 3.66

Capital Research Global Investors 3.25

State Street Corp 3.09

Vanguard Health Care Inv 3.01

NORGES BANK 2.70

Crestline Management LP 2.64

Baker Bros Advisors LP 2.55

Vanguard Total Stock Mkt Idx Inv 2.55

T. Rowe Price Investment Management,Inc. 2.22

American Funds SMALLCAP World A 2.19

iShares Russell 2000 ETF 2.17

Geode Capital Management, LLC 2.17

Baillie Gifford US Equity Growth 2.17

AllianceBernstein L.P. 2.15

Vanguard US Growth Investor 2.07

Vanguard Small Cap Index 1.93

Dimensional Fund Advisors, Inc. 1.65

T. Rowe Price Health Sciences 1.52

Point72 Asset Management, L.P. 1.51

Fidelity Growth Compy Commingled Pl S 1.39

Goldman Sachs Group Inc 1.28

Vanguard Small Cap Growth Index Inv 1.08

Fisher Asset Management, LLC 1.04

SPDR® S&P Biotech ETF 1.02

UBS (Lux) ES L/T Thms $Q 1.02

Fidelity Growth Company Fund 1.00

Vanguard Institutional Extnd Mkt Idx Tr 0.91

Fidelity Small Cap Index 0.91

Baillie Gifford American B Inc 0.88

UBS Lux Dgtl Hlth Eq Fd seeding P acc 0.87

US Small-Cap Growth II Equity Comp 0.79

T. Rowe Price New Horizons 0.79

Market Status

Strong Buy: 15

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 2616.45 M

PB Ratio 3.083

PE Ratio 0.0

Enterprise Value 2051.71 M

Total Assets 1374.18 M

Volume 1474308

Company Financials

Annual Revenue FY23:340814000 340.8M, FY22:108463000 108.5M, FY21:48661000 48.7M, FY20:335659000 335.7M, FY19:26678000 26.7M

Annual Profit FY23:null 0.0M, FY22:108463000 108.5M, FY21:48661000 48.7M, FY20:335659000 335.7M, FY19:26678000 26.7M

Annual Net worth FY23:-124429000 -124.4M, FY22:-325991000 -326.0M, FY21:-290581000 -290.6M, FY20:71136000 71.1M, FY19:-197614000 -197.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-101950000 -102.0M, Q2/2025:-3045000 -3.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-1942000 -1.9M

Quarterly Net worth Q3/2025:-126902000 -126.9M, Q2/2025:-124119000 -124.1M, Q1/2025:-132970000 -133.0M, Q3/2024:-107192000 -107.2M, Q2/2024:-99026000 -99.0M

Fund house & investment objective

Company Information Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 517

Industry Biotechnology

CEO Dr. Ryan J. Watts Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow